Dose prescription and treatment planning based on FMISO-PET hypoxia

Acta Oncologica

Volumn 51, Issue 2, 2012, Pages 222-230

  Toma Dasu, Iuliana ^a   Uhrdin, Johan ^b   Antonovic, Laura ^a   Dasu, Alexandru ^c,d   Nuyts, Sandra ^e   Dirix, Piet ^e   Haustermans, Karin ^e   Brahme, Anders ^f  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b RaySearch Laboratories AB   (Sweden)

^c Department of Clinical Immunology and Transfusion Medicine   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18;

ADULT; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; FEASIBILITY STUDY; HEAD AND NECK CANCER; HUMAN; HYPOXIA; INTENSITY MODULATED RADIATION THERAPY; LARYNX CANCER; MALE; OROPHARYNX CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOSENSITIVITY; TREATMENT OUTCOME; TREATMENT PLANNING;

ALGORITHMS; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; FEASIBILITY STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; RADIATION DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 84856502430     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.599815     Document Type: Article

References (51)

1. Brahme A. Individualizing cancer treatment: Biological optimization models in treatment planning and delivery. Int J Radiat Oncol Biol Phys 2001;49:327-37.
2. MacManus M, Nestle U, Rosenzweig KE, Carrio I, Messa C, Belohlavek O, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006 - 2007. Radiother Oncol 2009;91:85-94.
3. Apisarnthanarax S Chao KS. Current imaging paradigms in radiation oncology. Radiat Res 2005;163:1-25.
4. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, et al. Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;47:551-60.
5. Brahme A. Biologically optimized 3-dimensional in vivo predictive assay-based radiation therapy using positron emission tomography-computerized tomography imaging. Acta Oncol 2003;42:123-36.
6. Bentzen SM. Theragnostic imaging for radiation oncology: Dose-painting by numbers. Lancet Oncol 2005;6:112-7.
7. von Schulthess GK. Radiopharmaceuticals for clinical PET, PET-CT and SPECT-CT imaging. In: von Schulthess GK, editors. Molecular anatomic imaging: PET-CT and SPECTCT integrated modality, 2 nd ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 105 - 8.
8. Brahme A, Å gren AK. Optimal dose distribution for eradication of heterogeneous tumours. Acta Oncol 1987;26: 377-85.
9. Hö c kel M, Knoop C, Schlenger K, Vaupel P. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45-50.
10. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31-9.
11. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-7.
12. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, et al. Tumor hypoxia has independent predictor 230 I. Toma-Dasu et al. impact only in patients with node-negative cervix cancer. Clin Oncol 2002;20:680-7.
13. Denekamp J, Dasu A, Waites A. Vasculature and microenvironmental gradients: The missing links in novel approaches to cancer therapy? Adv Enzyme Regul 1998;38:281-99.
14. Dasu A, Toma-Dasu I. Treatment modelling: The infl uence of micro-environmental conditions. Acta Oncol 2008;47: 896-905.
15. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004;14:198-206.
16. Dasu A. Treatment planning optimisation based on imaging tumour proliferation and cell density. Acta Oncol 2008;47: 1221-8.
17. Thorwarth D, Alber M. Implementation of hypoxia imaging into treatment planning and delivery. Radiother Oncol 2010; 97:172-5.
18. Grosu AL, Souvatzoglou M, Roper B, Dobritz M, Wiedenmann N, Jacob V, et al. Hypoxia imaging with FAZAPET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 69:541-51.
19. Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18F-fl uoromisonidazole. Semin Nucl Med 2007;37:451-61.
20. Xing L, Cotrutz C, Hunjan S, Boyer AL, Adalsteinsson E, Spielman D. Inverse planning for functional image-guided intensity-modulated radiation therapy. Phys Med Biol 2002;47:3567-78.
21. Alber M, Paulsen F, Eschmann SM, Machulla HJ. On biologically conformal boost dose optimization. Phys Med Biol 2003;48:N31 - 5.
22. Das SK, Miften MM, Zhou S, Whiddon CS, Craciunescu O, Baydush AH, et al. Feasibility of optimizing the dose distribution in lung tumors using fl uorine-18-fl uorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions. Med Phys 2004;31:1452-61.
23. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: A planning study. Int J Radiat Oncol Biol Phys 2007;68:291-300.
24. Malinen E, Sovik A, Hristov D, Bruland OS, Olsen DR. Adapting radiotherapy to hypoxic tumours. Phys Med Biol 2006;51:4903-21.
25. S øv ik A, Malinen E, Bruland OS, Bentzen SM, Olsen DR. Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: A modelling study. Phys Med Biol 2007;52:499-513.
26. Flynn RT, Bowen SR, Bentzen SM, Rockwell MT, Jeraj R. Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. Phys Med Biol 2008;53:4153-67.
27. Ljungkvist ASE, Bussink J, Rijken PFJW, Kaanders JHAM, van der Kogel AJ, Denekamp J. Vascular architecture, hypoxia, and proliferation in fi rst-generation xenografts of human head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2002;54:215-28.
28. Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fl uoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995;33:391-8.
29. Roels S, Slagmolen P, Nuyts J, Lee JA, Loeckx D, Maes F, et al. Biological image-guided radiotherapy in rectal cancer: Is there a role for FMISO or FLT, next to FDG? Acta Oncol 2008;47:1237-48.
30. Nehmeh SA, Lee NY, Schroder H, Squire O, Zanzonico PB, Erdi YE, et al. Reproducibility of intratumor distribution of (18)F-fl uoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008;70:235-42.
31. Lee N, Nehmeh S, Schoder H, Fury M, Chan K, Ling CC, et al. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for headand- neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009;75:101-8.
32. Busk M, Horsman MR, Overgaard J. Resolution in PET hypoxia imaging: Voxel size matters. Acta Oncol 2008;47: 1201-10.
33. Toma-Dasu I, Dasu A, Brahme A. Dose prescription and optimisation based on tumour hypoxia. Acta Oncol 2009; 48:1181-92.
34. Dirix P, Vandecaveye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S. Dose painting in radiotherapy for head and neck squamous cell carcinoma: Value of repeated functional imagingwith (18)F-FDG PET, (18)F-fl uoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med 2009;50:1020-7.
35. Varghese AJ, Gulyas S, Mohindra JK. Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo. Cancer Res 1976;36:3761-5.
36. Chapman JD. The detection and measurement of hypoxic cells in solid tumors. Cancer 1984;54:2441-9.
37. Vaupel P, Hockel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 2007;9:1221-35.
38. Dasu A, Toma-Dasu I, Karlsson M. Theoretical simulation of tumour oxygenation and results from acute and chronic hypoxia. Phys Med Biol 2003;48:2829-42.
39. Toma-Dasu I, Uhrdin J, Dasu A, Brahme A. Therapy optimization based on non-linear uptake of PET tracers versus "linear dose painting". IFMBE Proceedings 2009;25/I:221-4.
40. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999;40:177-83.
41. Alper T, Howard-Flanders P. Role of oxygen in modifying the radiosensitivity of E. Coli B. Nature 1956;178:978-9.
42. Alper T. Cellular radiobiology. Cambridge: Cambridge University Press; 1979.
43. Hall EJ, Giaccia AJ. Radiobiology for the radiologist, 6t h ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
44. Douglas BG, Fowler JF. Fractionation schedules and a quadratic dose-effect relationship. Br J Radiol 1975;48:502-4.
45. Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 1982;8:1981-97.
46. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989;62:679-94.
47. Denekamp J, Dasu A. Inducible repair and the two forms of tumour hypoxia - time for a paradigm shift. Acta Oncol 1999;38:903-18.
48. Thames HD, Bentzen SM, Turesson I, Overgaard M, Van den Bogaert W. Time-dose factors in radiotherapy: A review of the human data. Radiother Oncol 1990;19:219-35.
49. Å gren Cronqvist AK, Kä l lman P, Turesson I, Brahme A. Volume and heterogeneity dependence of the dose-response relationship for head and neck tumours. Acta Oncol 1995; 34:851-60.
50. Deveau MA, Bowen SR, Westerly DC, Jeraj R. Feasibility and sensitivity study of helical tomotherapy for dose painting plans. Acta Oncol 2010;49:991-6.
51. Overgaard J. Hypoxic radiosensitization: Adored and ignored. J Clin Oncol 2007;25:4066-74